The College of New Jersey

Apply     Visit     Give     |     Alumni     Parents     Offices     TCNJ Today     

The 2018-2019 Novo Nordisk Lecture Series

 

The School of Science is pleased to host and sponsor the TCNJ–Novo Nordisk Lecture Series during the 2018-2019 academic year.


Fall 2018 Lecture

 

“Understanding How ‘Real world’ Data Help Improve Patient Outcomes”
Dr. Rahul Ganguly
Friday, October 12, 2018, 12:00-1:30pm (Lunch Reception & Lecture)
Education Building 212


Speaker

Dr. Rahul Ganguly, Executive Director of Health Economics Outcomes Research and Data Analytics, Novo Nordisk, Inc.

Date, Time, and Location

Friday, October 12, 2018
12:00 – 12:30 pm – Lunch Reception
12:30 – 1:20 pm – Lecture, Q&A, and Discussion
Education Building, Room 212

 

Click to enlarge.

Presentation Overview

In a continuation of the Novo Nordisk and TCNJ partnership, a Fall lecture will be held focusing on the current approaches to using “Real World” or “Big” Data to better understand and improve patient outcomes.  Dr. Rahul Ganguly, who leads the Health Economics Outcomes Research and Data Analytics team at Novo Nordisk, will review why real world data are so important in healthcare, different sources of real world data, and importantly how he and his team analyze and apply these data to help achieve improved outcomes for patients living with diabetes and obesity here in the United States.

 

About the Speaker

Dr. Rahul Ganguly has been with Novo Nordisk, Inc. since 2015 and is currently Executive Director of Health Economics and Outcomes Research (HEOR) & Real World Data analytics. In this role, he leads a team of managers conducting health economics and outcomes research across the Novo Nordisk product portfolio in diabetes, obesity, growth hormone, and hemophilia. Before joining Novo Nordisk, he spent 11 years working in HEOR roles of increasing responsibility at GlaxoSmithKline pharmaceuticals. He has worked in several disease areas, across the product development life-cycle and in global roles supporting outcomes research and HTA submissions in the United States, as well as key European and Asia Pacific countries. He has authored several scientific papers and presented in scientific congresses and holds a PhD in Pharmacoeconomics and Outcomes research.

 


Spring 2018 Lecture

 

“Diabetes is a Cardiovascular Disease – So Now We Need to Treat it as One”
Dr. Cory Gamble
Tuesday, February 19, 2019, 12:00-1:30pm (Lunch Reception & Lecture
Education Building 212


Speaker

Dr. Cory Gamble, DO, FACOI, FACE, Medical Director Novo Nordisk, Inc.

Date, Time, and Location

Tuesday, February 19, 2019
12:00-12:30 pm – Lunch reception
12:30-1:15 pm – Lecture, Q&A, and Discussion
Education Building, Room 212

 

Presentation Overview

Over the last 30 years, large scale trials have confirmed the importance of tight blood sugar control in order to avoid most of the long-term complications of both type 1 and type 2 diabetes. These same trials have been inconclusive around the importance of blood sugar control alone in order to avoid the number one most common complication for those persons with type 2 diabetes, heart attacks and strokes. Recent advancements in the understanding of the pathophysiology of type 2 diabetes have clearly shown that this disease involves much more than abnormal glucose, and many mechanisms are at work in creating a high risk for persons with diabetes in regards to these cardiovascular complications. Dr. Cory Gamble will review the current understanding of the multi-facet attack that is occurring on the blood vessels for those with type 2 diabetes, cover recent data indicating important considerations for use of therapies to treat type 2 diabetes, and review how just recently the diabetes treatment guidelines are changing to reflect this new approach.

 

About the Speaker

After Internship and a residency in Internal Medicine, Cory Gamble completed a fellowship in Endocrine and Metabolic Diseases and Hypertension at the University of Oklahoma. Cory is Board Certified in Internal Medicine and Endocrinology. He spent the next 21 years practicing all aspects of adult Endocrinology with multispecialty groups in Fort Smith, Arkansas. He worked for 18 years in the largest multispecialty clinic in Arkansas with 130 physicians. Cory joined Novo Nordisk as a Medical and Scientific Director in 2008. He went on to an Endocrine dedicated position as a Medical Liaison in 2010 and, from 2012 until 2014, he held a position as a Regional Medical Scientist. From 2013-2014 Cory served as the U.S. Chair of the NNI Research Grants Committee. Since 2014, Cory has been working in the U.S. Headquarters for Novo Nordisk in Plainsboro, first as the Medical Director for Victoza, including the U.S. Launch for the LEADER trial, and, since Fall 2018, as one of two U.S. Medical Directors for Oral Semaglutide.

 


TCNJ–Novo Nordisk Student Scholarships

In addition to sponsoring the Lecture Series, Novo Nordisk will support four Student Scholarships in the amount of $2,500 each for the 2019-2020 academic year. These scholarships will be competitively awarded to students who have attended the TCNJ–Novo Nordisk lectures during the 2018-2019 academic year and who have been deeply engaged in undergraduate research.

Student Eligibility and Application

Eligible students will include those in their Sophomore or Junior years who are pursuing a major in the School of Science. These students should have (1) attended at least one, but preferably both, of the Novo Nordisk lectures during the 2018-2019 academic year, (2) been deeply engaged in undergraduate research or a research-based internship, and (3) presented their work in a formal on-campus or off-campus professional setting (e.g., TCNJ’s Celebration of Student Achievement, a professional conference).

Eligible students will be invited to complete an application, which will include (a) demographic and academic information (e.g., academic major, year in the college, grade point average, etc.), (b) an essay on what they learned from participation in the TCNJ–Novo Nordisk lectures and how this connects with their coursework and/or signature experience work, (c) an essay on what they have learned from their signature experience work, and (d) an essay describing their aspirations and plans for pursuing their career. The four awardees will be competitively selected by a group of TCNJ faculty members.


TCNJ–Novo Nordisk Summer Research Fellowship

Novo Nordisk will also support TCNJ’s summer 2019 MUSE program, or Mentored Undergraduate Research Experience. Students interested in the MUSE program should discuss the program and summer opportunities with their faculty advisor.


About Novo Nordisk

novo nordiskHeadquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy, and hormone replacement therapy.

With the company’s U.S. headquarters located in Plainsboro, NJ, Novo Nordisk has long been committed to establishing programs throughout the Garden State that strive to make an impact in our local communities.  The TCNJ–Novo Nordisk Lecture Series, initiated in 2015-2016, is an exciting collaboration that provides students and faculty with the unique opportunity to learn and engage in a dialog with company leaders representing a variety of disciplines.


For More Information:

Top